A Self-Help Program for Memory CD8+ T Cells: Positive Feedback via CD40-CD40L Signaling as a Critical Determinant of Secondary Expansion

Jessica A. Shugart, Shelly Bambina, Alejandro F. Alice, Ryan Montler, Keith S. Bahjat*

Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Center, Portland, Oregon, United States of America

Abstract

The ability of memory CD8+ T cells to rapidly proliferate and acquire cytolytic activity is critical for protective immunity against intracellular pathogens. The signals that control this recall response remain unclear. We show that CD40L production by memory CD8+ T cells themselves is an essential catalyst for secondary expansion when systemic inflammation is limited. Secondary immunization accompanied by high levels of systemic inflammation results in CD8+ T cell secondary expansion independent of CD4+ T cells and CD40-CD40L signaling. Conversely, when the inflammatory response is limited, memory CD8+ T cell secondary expansion requires CD40L-producing cells, and memory CD8+ T cells can provide this signal. These results demonstrate that vaccination regimens that are in their dependence on CD40L-expressing CD8+ T cells for secondary expansion, and propose that CD40L-expression by CD8+ T cells is a fail-safe mechanism that can promote memory CD8+ T cell secondary expansion when inflammation is limited.

Introduction

A hallmark of the adaptive immune response is that a sublethal infection results in long-lived, antigen-specific immunity [1]. Memory CD8+ T cells (mCD8) are a critical component of the antigen-specific immune response based on their ability to respond rapidly to secondary infection by intracellular pathogens, move into peripheral tissues, and to kill infected cells via recognition of pathogen-derived peptides presented on MHC class I molecules [2,3]. While both naive CD8+ T cells and mCD8 receive signal one via TCR-mediated recognition of MHC class I-peptide complexes, these T cell populations differ in their location, phenotype and frequency. Thus, it is not surprising that regulation of a primary versus a secondary CD8+ T cell response involves both common and disparate elements. One such element is CD4+ T cell help. Similar to the primary CD8+ T cell response, the secondary function of mCD8 may require CD4+ T cell help [4,5], or it may proceed independent of CD4+ T cells [6,7].

Recent evidence suggests that the secondary function of mCD8 requires professional antigen presenting cells, costimulation and inflammatory cytokines [8–11]. Dendritic cell-expressed molecules such as IL-12p70, 4-1BBL and CD86 promote expansion of mCD8 [12]. Expression of these molecules by dendritic cells can occur via multiple signaling pathways, including inflammatory cytokines, TLR ligands, and cell-to-cell interaction. Interaction of T cell-produced CD40L and CD40-expressing dendritic cells (DCs) promotes DC survival, antigen processing and maturation [13,14]. These findings nonetheless leave many questions to be answered. In what physiologic context is CD40L required? If necessary, are CD4+ T cells solely responsible for delivering CD40L during the recall response? We therefore sought to investigate how the context of a secondary immunization influenced the need for CD4+ T cell help or CD40-CD40L signaling to promote mCD8 secondary expansion.

Expression of CD40L by CD8+ T cells can induce IL-12p70 production by dendritic cells and compensate for the lack of CD4+ T cell help during priming [14,16,17]. Here we found that CD4+ T cells were dispensable for mCD8 secondary expansion after immunization, but CD40-CD40L signaling was required. We then showed that a defined subset of memory CD8+ T cells rapidly produce CD40L following recognition of their cognate MHG-peptide complex. The necessity of CD40-CD40L signaling was dictated by the immunization regimen used. When mice were primed with vaccinia virus and boosted with attenuated L. monocytogenes, CD40-CD40L signaling was not required for mCD8 secondary expansion. Conversely, when mice were primed and boosted with attenuated L. monocytogenes, mCD8 secondary expansion required CD40-CD40L signaling but not CD4+ T cells. The requirement for CD40-CD40L signaling correlated with the in vivo persistence of the boosting vaccine and the elicited inflammatory milieu, but not the dose of antigen. We then showed that in vaccinia virus primed mice, accelerated clearance of the boosting L. monocytogenes vaccine by antibiotic treatment limited systemic inflammation and again led to CD40-CD40L-dependent mCD8 secondary expansion. Therefore, the inflammatory context of the secondary vaccination determines the necessity of CD40L expression for expansion, and CD40L-expressing mCD8 represent
a uniquely functional T cell subset capable of driving secondary expansion is limited.

**Materials and Methods**

**Mice**

6 to 10 week old C57BL/6 (C57BL/6j), B6.SJL (B6.SJL-Pepcb<sup>go f</sup> Ppr<sup>go f</sup>), and B6.Cd40L<sup>−/−</sup> (B6.129S2-Cd40<sup>−/−</sup>BoyJ) mice were obtained from The Jackson Laboratory. All animal protocols were approved by the Earle A. Chiles Research Institute’s IACUC.

**Vaccines and immunizations**

*L. monocytogenes* strains used for these studies, ActA-lm, ActA-lm-OVA (Lm-OVA, secreting chicken ovalbumin) and ActA-lm-QV (Lm-QV, expressing the class I-restricted vaccinia virus-derived epitopes B8R<sub>23–27</sub>, C4H<sub>142–112</sub>, A42R<sub>26–30</sub> and K3L<sub>15–19</sub> in addition to OVA257–264) lack the actin-polymerizing protein ActA and are unable to spread from cell to cell [18–20]. Bacteria were grown to stationary phase in brain-heart infusion broth, and CFU/organ was calculated. Colonies were enumerated using FlowJo (Treestar software) and SPICE v5.3 (http://exon.niaid.nih.gov/spice/).

**Flow cytometry**

Fluorochrome-conjugated antibodies specific for CD45.1 (clone A20), CD45.2 (clone 104), IFN-γ (clone XMG1.2), CD40L (clone MR1) (eBioscience) CD4 (clone GK1.5, except for CD4 depletion experiments when clone RM4-4 was used), CD8<sup>+</sup> (clone 53-6-7) and TNF (clone MP6-XT22) (BD Biosciences) were used at optimal titers as determined in our laboratory. Peptides for restimulation were obtained from A&A Labs.

**Bacterial clearance**

Spleens and livers were harvested into buffer containing 0.2% IgEgal at the indicated times following boost with 1 x 10<sup>7</sup> cfu ActA-Lm-QV. Organs were homogenized using an Omni Prep multi-sample homogenizer (Omni International) and plated on BHI plates containing streptomycin. Colonies were enumerated and CFU/organ was calculated.

**Serum cytokine analysis**

Serum cytokines were determined using the Mouse Inflammation Cytometric Bead Array (BD Biosciences). Samples were acquired on an LSRII flow cytometer and the exported data were analyzed using the CBA Analysis Plugin for Excel.

**Statistical Analyses**

Data represent at least two independent experiments, each containing 5 mice per experimental group. Error bars represent the standard error of the mean (SEM). Statistical analyses were performed for each independent experiment using a one-way ANOVA with Newman-Keuls post-test, or Mann-Whitney test where indicated.

**Results**

**Memory CD8<sup>+</sup> T cell expansion following homologous prime-boost is CD4<sup>+</sup> T cell independent but CD40L dependent**

We first asked if mCD8 secondary expansion following homologous prime-boost required CD4<sup>+</sup> T cell help. Evaluating the antigen-specific response 5 days post-boost minimizes the contribution of newly primed CD8<sup>+</sup> T cells to the analysis (Figure 1A). In all experiments, mice were fully immunocompetent at the time of the initial vaccination. Blocking or depleting antibodies were only used during the secondary immunization. Finally, to avoid the complications of neutralizing vector-specific antibodies, we used a live-attenuated *L. monocytogenes*-based vaccine for homologous prime-boost [24].

C57BL/6 (B6) mice were vaccinated with an attenuated *L. monocytogenes* expressing ovalbumin (Lm-OVA). Three weeks later, mice were depleted of CD4<sup>+</sup> cells and boosted with Lm-OVA.
Five days after the boosting immunization, OVA257–264-specific CD8+ T cells were enumerated using intracellular cytokine staining (Figures 1B,C). Neither the expansion nor the functionality of the memory CD8+ T cell population was affected by depletion of CD4+ T cells prior to boost. Therefore, homologous prime-boost with a live-attenuated *L. monocytogenes*-based vaccine elicited CD8+ T cell secondary expansion independent of CD4+ T cell help.

Given that CD4+ T cells were not required for mCD8 secondary expansion, we hypothesized that CD40L was also dispensable. To test this, B6 mice vaccinated with Lm-QV were boosted 21 days later with Lm-QV in the presence or absence of CD40L blockade. Interestingly, secondary expansion was limited by the absence of CD40–CD40L signaling (Figures 1D-E). Increasing the dose of Lm-QV used for the boost vaccination did not overcome the need for CD40–CD40L signaling. Therefore, optimal secondary mCD8 expansion following homologous prime-boost vaccination is independent of CD4+ T cell help, but is substantially enhanced by CD40–CD40L signaling.

Heterologous prime-boost maximizes mCD8 secondary expansion independent of CD40L signaling

The use of unique vectors expressing a common target antigen (i.e. heterologous prime-boost) can significantly improve the magnitude and potency of the T cell response relative to repeated vaccination with the same vector [25,26]. We asked if mCD8 secondary expansion after a heterologous prime-boost was also dependent on CD40–CD40L signaling. To address this question, B6 mice were primed with either vaccinia virus expressing ovalbumin (VV-OVA) or Lm-QV. Three weeks later, mice were depleted of CD4+ cells and then boosted with Lm-QV, with or without CD40L blockade. Five days later the expansion of antigen-specific CD8+ T cells was measured (Figure 2A). In contrast to homologous boost, mCD8 secondary expansion after heterologous prime-boost (VV-OVA prime, Lm-QV boost) was not dependent on CD40–CD40L signaling (Figures 2B–D). Similar patterns of expansion were observed for B8R20–27, and OVA257–264, CD8+ T cells. Because CD4+ cells were depleted prior to the boost, these cells could not be the source of CD40L. Thus, altering the priming and boosting vaccine vectors promoted optimal mCD8 secondary expansion without the need for CD40–CD40L signaling.

A distinct subset of memory CD8+ T cells produces CD40L

The divergent roles of CD4+ T cell help and CD40L signaling during homologous boost identified a role for non-CD4+ T cell expression of CD40L during secondary expansion. We asked if memory CD8+ T cells produce CD40L, and if so, if CD40L expression was homogeneous amongst the CD8+ T cells or restricted to subset of these cells. Lm-QV-primed mice were boosted with Lm-QV or HBSS 21 days later, and memory CD8+ T cells were analyzed for expression of CD40L 5 days following MR1 (sCD40L) or control antibody during boost. (C) Frequency of OVA257–264-specific CD8+ T cells within total CD8+ cells with and without CD40L blockade (mean±SEM, n=5). (D) Absolute number of IFN-γ-producing OVA257–264-specific CD8+ T cells (mean±SEM). (E) Fold expansion of OVA257–264-specific CD8+ T cells with and without CD40L blockade (mean absolute IFN-γ+ OVA257–264-specific CD8+ T cells per group relative to mean of matched HBSS group). *, P<0.05, **P<0.01, Mann-Whitney. Data are representative of two independent experiments.

doi:10.1371/journal.pone.0064878.g001

Figure 1. Memory CD8+ T cell expansion following homologous boost is CD4+ T cell independent but CD40L dependent.

Mice primed with Lm-OVA were boosted 21 days later with the indicated dose of Lm-OVA. 5 days post-boost, OVA257–264-specific CD8+ T cells were enumerated by IFN-γ intracellular cytokine staining. (A) CD8+ splenocytes were transferred from Lm-OVA primed B6.SJL (CD45.1+) mice into C57BL/6 (CD45.2+) recipients. Recipient mice were then treated with Lm-OVA and the frequency OVA257–264-specific CD8+ T cells was determined by intracellular IFN-γ staining. (B) Mice were depleted of CD4+ cells at the time of the secondary immunization. Absolute OVA257–264-specific CD8+ T cells five days post homologous Lm-OVA prime-boost (mean±SEM, n=5). (C-E) Mice were treated with MR1 (sCD40L) or control antibody during boost. (C) Frequency of OVA257–264-specific CD8+ T cells within total CD8+ cells with and without CD40L blockade (mean±SEM, n=5). (D) Absolute number of IFN-γ-producing OVA257–264-specific CD8+ T cells (mean±SEM). (E) Fold expansion of OVA257–264-specific CD8+ T cells with and without CD40L blockade (mean absolute IFN-γ+ OVA257–264-specific CD8+ T cells per group relative to mean of matched HBSS group). *, P<0.05, **P<0.01, Mann-Whitney. Data are representative of two independent experiments.

doi:10.1371/journal.pone.0064878.g001

Self-Help for Memory CD8+ T Cells

PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64878
While CD40L was undetectable in unstimulated CD8+ T cells, a brief (5 hour) restimulation with peptide and brefeldin A revealed a discrete subset of CD40L-expressing CD8+ T cells (Figure 3A). Importantly, CD40L was only detectable when cells were restimulated in the presence of the transport inhibitor brefeldin A. Using this technique, CD40L is retained within the cell and can be detected by intracellular staining. Co-staining with antibodies to IFN-γ, TNF, and CD40L revealed that not all IFN-γ and TNF double-positive CD8+ T cells can produce CD40L, but all CD40L-producing CD8+ T cells do produce IFN-γ and TNF. The subset of CD40L-producing CD8+ T cells was detectable after one or two immunizations, and was maintained within the memory CD8+ T cell pool, suggesting that a subset of mCD8 are programmed to express CD40L.

To identify the CD8+ T cell subsets capable of CD40L expression, we sorted antigen-specific T cells (identified by staining with Kb-B8R20–27 tetramers) into central memory (CD62L+/CD127−), effector memory (CD62L-/CD127+) subsets [27]. These populations were subsequently stimulated for 5 hours with the B8R20–27 peptide in the presence of brefeldin A and then stained for intracellular IFN-γ and CD40L (Figure 3B). CD8+ T cells with a memory phenotype (CD127+) were more likely to produce CD40L than the CD127- effector population. Within those CD127+ memory cells, the CD62L+ central memory subset was the most likely to produce CD40L. Based on these results, we hypothesize that CD62L+/CD127+ central memory CD8+ T cells are the most capable of producing CD40L.

To better understand the kinetics of CD40L expression by CD8+ T cells, splenocytes from mice primed with Lm-QV were restimulated for 1–5 hours with B8R20–27 and then stained for intracellular IFN-γ, TNF and CD40L (Figure 4). All three proteins were rapidly produced by CD8+ T cells, visible after 1 hour of restimulation (Figure 4A). The frequency of triple-positive CD8+ T cells increased over the first 4 hours of restimulation. After 5 hours of restimulation, expression of TNF and CD40L begins to wane and more cells producing only IFN-γ are seen (Figure 4B, C).

CD40L-expressing memory CD8+ T cells are sufficient to amplify secondary expansion

We next asked if mCD8-specific CD40L was indeed sufficient to maximize mCD8 secondary expansion. To test this, we primed wild-type CD8+ T cells (CD8+/Cd40L+/+) by immunizing B6.SJL mice with Lm-QV. Three weeks later, we transferred these antigen-experienced CD8+ T cells into recipients lacking CD40L (B6.Cd40L-/-) (Figure 5A). In this system, the only cells capable of producing CD40L are the transferred CD8+ Cd40L+/+ T cells. Recipient mice were primed prior to adoptive transfer to establish Lm-specific immunity and recreate the conditions of homologous prime-boost. Preliminary experiments confirmed that Lm-QV was cleared with similar kinetics from previously immunized B6 and B6.Cd40L-/- mice (data not shown). 24 hours after adoptive transfer, mice were immunized with Lm-QV and 5 days later, Ag-specific CD8+ T cells were enumerated. Donor CD8+/Cd40L+/+ cells placed into recipients lacking CD40L were expanded 40-fold compared to 10-fold in recipients receiving donor CD8+ T cells alone (Figure 5B). This demonstrates that CD40L-expressing memory CD8+ T cells are sufficient to amplify secondary expansion.

Figure 2. CD40L is required for mCD8+ T cell expansion following homologous (but not heterologous) boost, in the absence of CD4+ T cells. Mice were primed with 10⁷ cfu Lm-QV or 10⁶ pfu VV-OVA and boosted 21 days later with 10⁷ cfu Lm-QV. Starting on day 20 (1 day pre-boost), mice were depleted of CD4+ T cells. MR1 (αCD40L) or control antibody was administered to indicated groups during boost. OVA257–264-specific CD8+ T cell responses were assessed 5 days post-boost by intracellular cytokine staining. (A) Frequency of OVA257–264-specific CD8+ T cells within total CD8+ T cells (mean±SEM, n = 5). (B) Total IFN-γ+ OVA257–264-specific or B8R20–27-specific mCD8+ T cells per spleen (mean±SEM). (C) Fold expansion of OVA257–264-specific or B8R20–27-specific CD8+ T cells after homologous or heterologous boost. (mean absolute IFN-γ+ OVA257–264 -specific CD8+ T cells per group relative to mean of matched HBSS group). Data are representative of two independent experiments. doi:10.1371/journal.pone.0064878.g002
T cells promote secondary expansion following homologous boost. Expression in non-boosted, day 21 splenocytes were sorted into central memory (CD127+CD62L-) and effector memory (CD127−CD62L+) subsets. Sort purified cells were incubated for five hours with B8R20–27 peptide in the presence of brefeldin A, and then stained for CD4, CD8, and intracellular IFN-γ.

Figure 3. CD40L expressing mCD8+ T cells promote secondary expansion following homologous boost. (A) Mice primed with 10^7 cfu Lm-QV were boosted 21 days later with HBSS or 10^5 cfu Lm-QV. 5 days following boost, splenocytes were restimulated with OVA257–264 in the presence of brefeldin A, and then stained with antibodies for CD4, CD8, and intracellular IFN-γ. Left panels demonstrate CD40L expression in non-boosted, day 21+5 OVA257–264-specific CD8+ T cells. Right panels represent OVA257–264-specific CD8+IFN-γ+/TNF-/CD40L- cells 5 days after boosting with Lm-QV. (B) Mice were primed and boosted with 10^7 cell Lm-QV. Five days after the boost, CD8+B8R20–27-specific splenocytes were sorted into central memory (CD127+CD62L+) and effector memory (CD127−CD62L-) subsets. Sort purified cells were incubated for five hours with B8R20–27 peptide in the presence of brefeldin A, and then stained for CD4, CD8, and intracellular IFN-γ.

Rapid clearance of homologous vaccine vector during secondary immunization limits inflammation and correlates with increased CD40L dependence

Antigen-specific mCD8 are the principal mediators of protective immunity to L. monocytogenes [28]. We hypothesized that the discordant requirement for CD40-CD40L signaling between homologous and heterologous prime-boost would be explained by different rates of vaccine clearance following secondary immunization. Although Lm-QV and VV-OVA share 5 class I-restricted epitopes, the adaptive response toward the other 3,000 proteins expressed by Lm-QV following a homologous boost could play a significant role in vaccine clearance. To determine how the homologous or heterologous prime affected clearance of the secondary vaccine, B6 mice were primed with VV-OVA or Lm-QV and then three weeks later, boosted with Lm-QV. We enumerated Lm-QV CFU in the spleen and liver between 1 and 72 hours after vaccination (Figure 6A), and quantified serum cytokines at 4 and 24 hours (Figure 6B). As predicted, vaccine was cleared substantially faster in vaccinated versus naïve mice. Mice primed with Lm-QV completely cleared the Lm-QV boost within 24 hours of vaccination. Mice primed with VV-OVA required 72 hours before Lm-QV was eradicated from both spleen and liver.

Delayed clearance of the boosting vector increased the innate inflammatory response, where serum concentrations of IFN-γ, MCP-1 and IL-6 negatively correlated with the rate of Lm-QV clearance (Figure 6B). Therefore, the breadth of vector specific immunity correlates with the kinetics of vaccine clearance during secondary immunization, the innate inflammatory response, and the dependence on CD40L to promote mCD8 secondary expansion.

In addition to limiting inflammation, accelerated clearance of Lm-QV may decrease the quantity of antigen available for processing and presentation. If antigen load were the determinate of CD40L-dependence or independence, then normalizing the antigen concentration should eliminate the disparity in CD40L-dependence between homologous and heterologous prime-boost. To test this, B6 mice were primed with Lm-OVA or VV-OVA. Three weeks later, mice were boosted using DEC-205-OVA. This DEC-205-specific antibody delivers ovalbumin to DEC-205-expressing dendritic cells for processing and presentation [29]. We then injected a L. monocytogenes strain with the same attenuating deletion as Lm-OVA, but without the OVA antigen expression cassette. In this model system, all mice receive an equivalent dose of antigen (ovalbumin, delivered by DEC-205-OVA) irrespective of how quickly the Lm is cleared. The Lm serves only as an adjuvant in these experiments. Finally, mice were treated with anti-CD40L or hamster IgG and the frequency of OVA257–264-specific CD8+ T cells was determined five days later (Figure 6C). Immunization with DEC-205-OVA alone does not elicit mCD8 secondary expansion, reinforcing the need for some degree of inflammation for secondary expansion. Consistent with our hypothesis, mCD8 in mice primed with Lm-OVA underwent secondary expansion that was CD40L dependent (Figure 6D). Conversely, mice primed with VV-OVA demonstrated mCD8 secondary expansion that was independent of CD40-CD40L signaling. Thus, independent of antigen concentration, vector-specific immunity determines the necessity of CD40-CD40L signaling for mCD8 secondary expansion.

Truncating secondary infection recapitulates the CD40-CD40L dependence of the homologous boost

If delayed clearance of Lm allows CD40-CD40L independent mCD8 secondary expansion after a heterologous boost, then accelerating Lm clearance should increase the dependence on...
CD40-CD40L signaling. To test this hypothesis, mice were primed with VV-OVA and then three weeks later, boosted with Lm-QV with and without CD40L blockade. Mice were treated with ampicillin eight hours after secondary immunization to accelerate Lm-QV clearance. Five days after boosting, mCD8 secondary expansion was assessed by enumerating antigen-specific CD8+ T cells. Accelerating Lm-QV clearance with ampicillin treatment recapitulated the CD40-CD40L dependence of mCD8 secondary expansion observed after homologous prime-boost (Figures 7A,B). CD40L dependence correlated with decreased concentrations of IFN-γ, IL-6, MCP-1 and TNF in the serum (Figure 7C). These results confirm that accelerated clearance of the boosting vaccine vector decreases inflammation thereby necessitating CD40L expression by mCD8 to maximize secondary expansion.

Discussion

Our data demonstrate that CD40L-expressing mCD8 can promote their own secondary expansion when inflammation is limited. It is appreciated that antigen-specific CD8+ T cells can compensate for a lack of CD4+ T cell help during priming via a CD40L-dependent mechanism [15,16]. In addition to MHC-peptide and costimulatory signals, CD8+ T cell priming requires a third signal, which can be delivered via IL-12p70 or type I IFN [30]. DCs express CD40, and combined signals via TLRs and CD40 result in production of IL-12p70 and upregulation of costimulatory molecules such as CD70, CD86 and 4-1BB [12,17]. In vitro, CD8+ T cells promote CD40-dependent IL-12p75 production by CD8α+ DCs [31]. In addition, the IFN-γ-
driven production of IL-18 by the DC can be important for secondary expansion and may be impacted by CD40L-expressing CD8+ T cells [32]. While the minimal 'signal three' requirements for the antigen-experienced CD8+ T cell are unclear, we hypothesize that rapid production of CD40L, together with IFN-γ, licenses the antigen-presenting DC for IL-12p70 and IL-18 production, which subsequently drives secondary expansion. This process is likely to occur through the CD8α+ DC, as they are uniquely equipped for cross-presentation of exogenous antigen via the class I pathway [33].

In the context of CD8+ T cell-mediated immunity to intracellular microbes, the capacity for mCD8 to proliferate in response to low levels of inflammation is critical to their functionality. The initial infectious dose during a typical infection is unlikely to elicit the kind of immediate cytokine release observed in our vaccination model. One could envision that during the course of a natural secondary infection, a limited amount of inflammation will accompany presentation of pathogen-derived peptides on class I MHC. By virtue of their location, increased frequency, and increased ability to respond to peptide-MHC, the

Figure 5. CD40L expressing mCD8+ T cells promote secondary expansion following homologous boost. (A) Experimental design: Donor (B6.SJL) mice and recipient (C57BL/6 and CD40L-deficient) mice were concurrently primed with 10⁷ cfu Lm-QV. 21 days later, CD8+ T cells were purified from B6.SJL spleens and transferred into B6 and B6.CD40L/-/- mice. 24 h post-transfer, recipients were boosted with 5 x 10⁶ cfu Lm-QV in the presence of αCD40L or control antibody. OVA257–264-specific memory CD8+ T cell responses were assessed 5 days following boost using intracellular cytokine staining for IFN-γ (n = 5). (B) Total OVA257–264-specific (IFN-γ+) CD45.1+CD8+ T cells per animal (mean, ± SEM). *, P < 0.05, **, P < 0.01, Mann-Whitney. (C) Fold expansion of donor CD45.1+ IFN-γ + OVA257–264-specific CD8+ T cells. Data are representative of three independent experiments. doi:10.1371/journal.pone.0064878.g005

Figure 6. Accelerated clearance of homologous vaccine vector limits inflammation and correlates with increased CD40L dependence. (A–B) Mice were primed with 10⁷ cfu Lm-OVA, 10⁶ pfu VV-OVA, or HBSS and boosted 21 days later with 10⁷ cfu Lm-QV (n = 5). (A) Spleens and livers were harvested at 24, 48, and 72 hours following boost, and cfu were enumerated by plating organ homogenates (mean, ± SEM). (B) Serum cytokine levels at 4 and 24 h following boost (mean, ± SEM). (C–E) Mice were primed with 10⁷ cfu Lm-OVA or 10⁶ pfu VV-OVA and boosted 21 days later with 5 μg DEC205-OVA alone, 5 μg DEC205-OVA with 10⁷ cfu Lm-OVA, or HBSS. αCD40L or control antibody was administered to the indicated groups during boost. OVA257–264-specific memory CD8+ T cell responses were assessed 5 days post-boost using intracellular cytokine staining for IFN-γ (n = 5). (C) Representative plots of OVA257–264-specific T cell enumeration (median shown, ± SEM). (D) Total OVA257–264-specific (IFN-γ+) CD8+ T cells per animal (mean, ± SEM). *, P < 0.05, **, P < 0.01, ***, P < 0.001, ANOVA. Data are representative of two independent experiments. doi:10.1371/journal.pone.0064878.g006
antigen-specific mCD8 population can rapidly respond to prevent disseminated infection. In this scenario, it could be the intrinsic CD40L-expression by mCD8 that synergizes with the localized inflammatory response and drives mCD8 secondary expansion. Thus, CD40L-expression by antigen-specific CD8+ T cells may reflect the potency of those cells and predict their effectiveness in preventing infection.

These studies offer insight into the favorable adaptive immune responses elicited by heterologous prime-boost immunization regimens [34,35]. The primary hurdle this approach overcomes is the induction of vector-specific humoral immunity and attenuated responsiveness to subsequent vaccinations. In the case of viral-based vaccine vectors, antibodies specific for viral proteins impair viral entry, limit expression of the encoded disease-specific antigen and ultimately, presentation of the relevant MHC-peptide complexes [36]. Yet despite the demonstrated potency of this vaccination approach, little is known mechanistically beyond the avoidance of neutralizing humoral immunity [37]. Our data demonstrate that secondary immunization with a heterologous vaccine vector reduces the speed with which the secondary vaccine is cleared, increasing the innate inflammatory response and overcoming not only the requirement for CD4+ T cell help, but also CD40-CD40L signaling.

While these studies address previous discrepancies regarding the necessity of CD4+ help and CD40 signaling during the secondary response, they also pose a new set of questions. Why do only a subset of antigen-specific CD8+ T cells express CD40L after restimulation? Were these cells primed differently, or do they express TCRs with higher affinity for their cognate peptide-MHC? While the conditions required during priming to elicit a CD40L-expressing mCD8 population are unknown, it is unlikely that all vaccines are equivalent in this respect - especially if the goal is to activate a self-reactive CD8+ T cell population. In this case, the use of a heterologous boosting vector that elicits a substantial inflammatory response will promote secondary expansion of mCD8 whether or not those mCD8 express CD40L. So while the expression of CD40L by CD8+ T cells may reflect the priming conditions, the necessity of those CD40L-expressing mCD8 for a recall response can be mitigated through the use of a pro-inflammatory heterologous vaccine.

The utility of heterologous prime-boost should also be considered in light of pre-existing immunity to many microbial vaccine vectors. For example, clinical trials using L. monocytogenes-based vaccine vectors must contend with patients that have been exposed to L. monocytogenes repeatedly over their lifetime [24,38,39]. In this context, the presence of Listeria-specific CD8+ T cells could either help (via CD40L-dependent licensing of DCs) or hurt the T cell response (via rapid killing of APCs presenting both Listeria- and tumor-associated epitopes). Retrospective analyses of banked PBMC from human vaccination clinical trials may be informative in this regard, based on the hypothesis that vaccines that elicit CD40L-expressing CD8+ T cells would provide superior antigen-specific immunity.

Acknowledgments

We would like to thank Pete Lauer (Aduro Biotech) for providing recombinant L. monocytogenes strains; Tibor Keler and Laura Vitale (CellDex Therapeutics) for providing DEC205-OVA; Maria-Luisa Alegre, Michael Gough, Marka Crittenden, and Will Redmond for helpful review of the manuscript and insightful discussions of data.

Author Contributions

Conceived and designed the experiments: JAS SB RM AFA KSB. Performed the experiments: JAS SB RM AFA. Analyzed the data: JAS AFA KSB. Wrote the paper: JAS KSB.

References

1. Ahmed R, Gray D (1996) Immunological memory and protective immunity: understanding their relation. Science 272: 54–60.
2. Pihlgren M, Dubois PM, Tomkowiak M, Sjogren T, Marvel J (1996) Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med 184: 2141–2151.
3. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B (2000) CD8 T cell help, but not CD40-CD40L signaling, can stimulate T cell expansion and differentiation in vivo. Nat Med 6: 1292–1297.
4. Ryu SJ, Jung KM, Yoo HS, Kim TW, Kim S, et al. (2009) Cognate CD4 help is independently to facilitate robust CD8 and CD4 recall responses. J Immunol 183: 3492–3501.
5. Jansen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, et al. (2003) CD8+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852–856.
6. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337–339.
7. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300: 339–342.
8. Davicki W, Bertram EM, Sharpe AH, Watts TH (2004) 4-IBB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 173: 3944–3951.
9. Gariou L, Heydari S, Truong P, Brooks DG, McGavern DB (2009) Therapeutic memory T cells require costimulation for effective clearance of a persistent viral infection. J Virol 83: 8905–8915.

Figure 7. Antibiotic treatment following heterologous boost recapitulates dependence on CD40L for mCD8+ T cell expansion. Mice were immunized with 10^6 pfu VV-OVA and boosted 21 days later with 5×10^6 cfu Lm-QV in the presence of MR1 or control antibody treatment. 8 hours following boost, indicated groups were treated with ampicillin to accelerate bacterial clearance. OVA257–264-specific memory CD8+ T cell responses were assessed 5 days post-boost using intracellular cytokine staining for IFN-γ (n = 5). (A) Representative intracellular cytokine staining (median shown, ± SEM). (B) Total OVA257–264-specific (IFN-γ+) CD8+ T cells (mean, ± SEM), * P<0.05, Mann-Whitney. (C) Serum cytokines 24 h post-boost in untreated versus ampicillin-treated animals (mean, ± SEM). Data are representative of three independent experiments. doi:10.1371/journal.pone.0064878.g007
10. Malaranann S, Mendoula LM, Shastri N (2001) Generation of antigen-specific, lacZ-inducible T-cell hybrid. Methods Mol Biol 156: 265–272.

11. Borowski AB, Boesteanu AC, Mueller YM, Carafides C, Topfham DJ, et al. (2007) Memory CD8+ T cells require CD28 costimulation. J Immunol 179: 6494–6503.

12. Bertram EM, Dawicki W, Sedgmen B, Bramson JL, Lynch DH, et al. (2004) A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo. J Immunol 173: 981–988.

13. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten C, et al. (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med 180: 1263–1272.

14. Fuji S, Liu K, Smith C, Bonito AJ, Steinman RM (2004) The linkage of innate responses in the absence of CD4+ cell responses to vaccinia virus. Nat Biotechnol 22: 817–819.

15. Whitmore JK, Flavell RA, Grevel IS, Larson CP, Pearson TC, et al. (1999) CD40-CD40 ligand costimulation is required for generating antiviral CD4+ T cell responses but is dispensable for CD8+ T cell responses. J Immunol 163: 3194–3201.

16. Hernandez MG, Shen L, Rock KL (2007) CD40-CD40 ligand interaction between dendritic cells and CD8+ T cells is needed to stimulate maximal T cell responses in the absence of CD4+ T cell help. J Immunol 178: 2844–2852.

17. Abdi K, Singh N, Matzinger P (2006) T-cell control of IL-12p70 production. Scand J Immunol 64: 83–92.

18. Kocks C, Gouin E, Tabouret M, Berche P, Ohayon H, et al. (1992) Monocytogenes-induced actin assembly requires the acta gene product, a surface protein. Cell 68: 521–531.

19. Mounta M, Peters B, Pasqueto V, Tscharke DC, Sidney J, et al. (2006) A consensus epitope prediction approach identifies the breadth of murine surface protein. Cell 68: 521–531.

20. Lauer P, Hanson B, Lemmens EE, Liu W, Luckett WS, et al. (2008) Constitutive Cytosolic entry controls CD8+ T-cell potency during bacterial infection. Infect Immun 76: 3742–3753.

21. Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, et al. (2007) Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315: 1657–1661.

22. Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, et al. (2006) Cytosolic entry controls CD8+ T-cell potency during bacterial infection. Infect Immun 74: 6387–6397.

23. Bahjat KS, Meyer-Morse N, Lemmens EE, Shugart JA, Dubensky TW, et al. (2009) Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria. PLoS Pathog 5: e1000568.

24. Leong ML, Hampl J, Liu W, Mathur S, Bahjat KS, et al. (2009) Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in human and modeling studies using recombinant vaccines in mice. Infect Immun 77: 3950–3960.

25. Lu S (2009) Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346–351.

26. Devrient B, Barret K, Dierendouck M, Favoreel H, De Koker S, et al. (2012) One-step spray-dried polyelectrolyte microparticles enhance the antigen cross-presentation capacity of primary dendritic cells. Eur J Pharm Biopharm.

27. Huster KM, Busch V, Schiemann M, Linkemann K, Kerksiek KM, et al. (2004) Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A 101: 5610–5615.

28. Pamert EG (2004) Immune responses to Listeria monocytogenes. Nat Rev Immunol 4: 812–823.

29. Bonifazi I, Bonnyay D, Mahlke K, Rivera M, Nussenzweig MC, et al. (2002) Efficient targeting of protein antigen to the dendritic cell receptor DEC205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627–1638.

30. Curtissinger JM, Moscher MF (2010) Inflammatory cytokines as a third signal for T-cell activation. Curr Opin Immunol 22: 335–340.

31. Wong KL, Tang LF, Lew FC, Wong HS, Chua YL, et al. (2009) CD8+ High memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production. J Immunol 183: 41–50.

32. Malaranann S, Horng T, Shih PP, Schob S, Shastri N (1999) Presentation of out-of-frame peptide/MHC class I complexes by a novel translation initiation mechanism. Immunol 10: 681–690.

33. Joffre OP, Segura E, Savina A, Amidogena S (2012) Cross-presentation by dendritic cells. Nat Rev Immunol 12: 537–546.

34. Stackhouse S, Ghandehari A, Niazi K, Ammendola V, et al. (2010) Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCl353 and MVA prime-boost immunisation in non-human primates. Vaccine 29: 2546–2553.

35. Kanto PW, Schultz TJ, Blumenstein BA, Glode LM, Bihlartz DL, et al. (2010) Overall survival analysis of a phase II randomized controlled trial of a Prokial-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099–1105.

36. Wirth TC, Marin MD, Starbeck-Miller G, Harty JT, Badovinac VP (2011) Secondary CD8+ T-cell responses are controlled by systemic inflammation. Eur J Immunol 41: 1321–1333.

37. Thompson CH, Rose BR, Cossart YE (1992) Detection of HPV DNA in archival specimens of cervical cancer using in situ hybridization and the polymerase chain reaction. J Med Virol 36: 54–59.

38. Maciag PG, Radulovic S, Rothman J (2009) The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-Expressing Mesothelin (CRS-207) for Advanced Cancers. Cancer Res Express Mosothelin (CRS-207) for Advanced Cancers: Phase 1 Studies of Safety and Immune Induction. Clin Cancer Res.